CTI BioPharma Corp. (NASDAQ:CTIC) caters to the Healthcare space. Its weekly performance is -4.38%. On the last day of trading company shares ended up $1.53. CTI BioPharma Corp. (NASDAQ:CTIC) distance from 50-day simple moving average (SMA50) is -17.74%.
CTI BioPharma Corp. (CTI), formerly Cell Therapeutics, Inc., is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers. The Company is focused on commercializing PIXUVRI (pixantrone), or PIXUVRI, in the European Union, for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL), and conducting a Phase III clinical trial program of pacritinib for the treatment of adult patients with myelofibrosis to support regulatory submission for approval in the United States and Europe.
Roth Capital reiterated their buy rating on shares of CTI BioPharma Corp. (NASDAQ:CTIC) in a resaerch note published on Friday, AnalystRatings.NET reports. Roth Capital currently has a $4.50 price target on the biopharmaceutical company’s stock.
Hooker Furniture Corp. (NASDAQ:HOFT) ended the last trading day at $23.59. Company weekly volatility is calculated as 3.14% and price to cash ratio as 6.30. Hooker Furniture Corp. (NASDAQ:HOFT) showed a weekly performance of 2.17%.
Hooker Furniture Corporation is a home furnishings marketing, design and logistics company offering sourcing of residential casegoods and upholstery, as well as domestically-produced custom leather and fabric-upholstered furniture. The Company’s segments are casegoods furniture, upholstered furniture and all other. Its casegoods product categories include accents, home office, dining, bedroom and home entertainment furniture under the Hooker Furniture brand.
Hooker Furniture Corp. (NASDAQ:HOFT) said that, it will present its fiscal 2016 second quarter and first-half financial results via teleconference and live internet web cast on Thursday afternoon, September 3 at 2:00 PM Eastern Time.
On 01 September, Avon Products Inc. (NYSE:AVP) shares decreased -8.48% and was closed at $4.75. AVP EPS growth in last 5 year was -21.30%. Avon Products Inc. (NYSE:AVP) year to date (YTD) performance is -48.17%.
Avon Products, Inc. is a manufacturer and marketer of beauty and related products. The Company’s offers its products under two product categories: Beauty and Fashion & Home. Beauty consists of skincare (which includes personal care), fragrance and color (cosmetics). Fashion & Home consists of fashion jewelry, watches, apparel, footwear, accessories, gift and decorative products, housewares, entertainment and leisure products, children’s products and nutritional products. The Company’s segments are -based on geographic operations and include commercial business units in Latin America; Europe, Middle East & Africa; North America, and Asia Pacific.
On 18 August, Avon Products Inc. (NYSE:AVP) said that, it is seeking approval of a $62 million settlement of a U.S. lawsuit accusing the cosmetics company of defrauding shareholders by concealing its failure to stop workers from bribing officials in China to win business.
Ocata Therapeutics, Inc. (NASDAQ:OCAT) shares advanced 3.55% in last trading session and ended the day at $4.38. OCAT Gross Margin is 50.00% and its has a return on assets of -189.10%. Ocata Therapeutics, Inc. (NASDAQ:OCAT) quarterly performance is -30.48%.
Ocata Therapeutics, Inc., formerly Advanced Cell Technology, Inc., is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company’s advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders.
On 1 September, Ocata Therapeutics, Inc. (NASDAQ:OCAT) announced that it has been awarded a Small Business Innovation Research (SBIR) grant from the National Eye Institute (NEI), part of the National Institutes of Health (NIH), to fund Investigational New Drug (IND)-enabling preclinical development of Ocata’s proprietary photoreceptor progenitor product for the treatment of retinal degenerative diseases, such as retinitis pigmentosa (RP) and photoreceptor dystrophies.
Comcast Corporation (NASDAQ:CMCSA) caters to the Services space. It has a net profit margin of 12.30% and weekly performance is 2.17%. On the last day of trading company shares ended up $55.02. Comcast Corporation (NASDAQ:CMCSA) distance from 50-day simple moving average (SMA50) is -9.36%.
Comcast Corporation is a media and technology company. The Company has two primary businesses, Comcast Cable and NBCUniversal. The Company’s business line comprises five segments: Cable Communications; Cable Networks; Broadcast Television; Filmed Entertainment, and Theme Parks. Cable Communications consists of the operations of Comcast Cable, a provider of video, high-speed Internet and voice services under the XFINITY brand.
On 31 August, Comcast Corporation (NASDAQ:CMCSA) announced that Myrna Soto has been promoted to Senior Vice President, Global Chief Information Security Officer (GCISO). In this new role, Ms. Soto is responsible for the alignment and development of cyber and data security strategies and policies across the entire Comcast enterprise, including Comcast Cable, NBCUniversal and Comcast Spectacor. She reports to Michael Cavanagh, Senior Executive Vice President and Chief Financial Officer of Comcast Corporation.